Distribution and antifungal susceptibility of Candida species causing candidemia from 1996 to 1999

Diagnostic Microbiology and Infectious Disease

Volumn 48, Issue 1, 2004, Pages 33-37

  Cheng, Ming Fang ^a,b,c   Yu, Kwok Woon ^a   Tang, Ran Bin ^a   Fan, Yu Hua ^d   Yang, Yun Liang ^e   Hsieh, Kai Sheng ^a   Ho, Monto ^b   Lo, Hsiu Jung ^b  

^a KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^e NATIONAL CHIAO TUNG UNIVERSITY   (Taiwan)

Author keywords

Antifungal susceptibility; Candida species; Candidemia; Resistance

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BLOOD SAMPLING; CANDIDA; CANDIDA ALBICANS; CANDIDA CIFERRII; CANDIDA GLABRATA; CANDIDA GUILLIERMONDII; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDIASIS; CLASSIFICATION; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; EPIDEMIOLOGY; FUNGEMIA; FUNGUS ISOLATION; HUMAN; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; NONHUMAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

CANDIDA; CANDIDA ALBICANS; CANDIDA CIFERRII; CANDIDA GLABRATA; CANDIDA GUILLIERMONDII; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS;

EID: 0842281444     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2003.08.002     Document Type: Article

References (25)

1. Bulmer G.S., Marquez M.L., Co-Barcelona L., Fromtling R.A. Yeasts and fluconazole susceptibility in the Philippines. Mycopathologia. 146:1999;117-120.
2. Chakrabarti A., Mohan B., Shrivastava S.K., Marak R.S., Ghosh A., Ray P. Change in distribution and amp; antifungal susceptibility of Candida species isolated from candidaemia cases in a tertiary care centre during 1996-2000. Indian J Med Res. 116:2002;5-12.
3. Colombo A.L., Nucci M., Salomao R., Branchini M.L., Richtmann R., Derossi A., Wey S.B. High rate of non-albicans candidemia in Brazilian tertiary care hospitals. Diagn Microbiol Infect Dis. 34:1999;281-286.
4. de Gentile L., Bouchara J.P., Cimon B., Chabasse D. Candida ciferrii clinical and microbiological features of an emerging pathogen . Mycoses. 34:1991;125-128.
5. de Gentile L., Bouchara J.P., Le Clec'h C., Cimon B., Symoens F., Chabasse D. Prevalence of Candida ciferrii in elderly patients with trophic disorders of the legs. Mycopathologia. 131:1995;99-102.
6. Furman R.M., Ahearn D.G. Candida ciferrii and Candida chiropterorum isolated from clinical specimens. J Clin Microbiol. 18:1983;1252-1255.
7. Gunsilius E., Lass-Florl C., Kahler C.M., Gastl G., Petzer A.L. Candida ciferrii, a new fluconazole-resistant yeast causing systemic mycosis in immunocompromised patients. Ann Hematol. 80:2001;178-179.
8. Hsueh P.R., Teng L.J., Yang P.C., Ho S.W., Luh K.T. Emergence of nosocomial candidemia at a teaching hospital in Taiwan from 1981 to 2000 increased susceptibility of Candida species to fluconazole . Microb Drug Resist. 8:2002;311-319.
9. Jarvis W.R. Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis. 20:1995;1526-1530.
10. Kao A.S., Brandt M.E., Pruitt W.R., Conn L.A., Perkins B.A., Stephens D.S., Baughman W.S., Reingold A.L., Rothrock G.A., Pfaller M.A., Pinner R.W., Hajjeh R.A. The epidemiology of candidemia in two United States cities results of a population-based active surveillance . Clin Infect Dis. 29:1999;1164-1170.
11. Karlowsky J.A., Zhanel G.G., Klym K.A., Hoban D.J., Kabani A.M. Candidemia in a Canadian tertiary care hospital from 1976 to 1996. Diagn Microbiol Infect Dis. 29:1997;5-9.
12. Kontoyiannis D.P. Why prior fluconazole use is associated with an increased risk of invasive mold infections in immunosuppressed hosts an alternative hypothesis . Clin Infect Dis. 34:2002;1281-1283.
13. Kovacicova G., Krupova Y., Lovaszova M., Roidova A., Trupl J., Liskova A., Hanzen J., Milosovic P., Lamosova M., Macekova L., Szovenyiova Z., Purgelova A., Obertik T., Bille J., Krcmery V. Antifungal susceptibility of 262 bloodstream yeast isolates from a mixed cancer and non-cancer patient population is there a correlation between in-vitro resistance to fluconazole and the outcome of fungemia? J Infect Chemother. 6:2000;216-221.
14. Krcmery V., Barnes A.J. Non-albicans Candida spp. causing fungaemia pathogenicity and antifungal resistance . J Hosp Infect. 50:2002;243-260.
15. Lee S.C., Fung C.P., Chen H.Y., Li C.T., Jwo S.C., Hung Y.B., See L.C., Liao H.C., Loke S.S., Wang F.L., Lee J.C. Candida peritonitis due to peptic ulcer perforation incidence rate, risk factors, prognosis and susceptibility to fluconazole and amphotericin B . Diagn Microbiol Infect Dis. 44:2002;23-27.
16. Mardani M., Hanna H.A., Girgawy E., Raad I. Nosocomial Candida guilliermondii fungemia in cancer patients. Infect Control Hosp Epidemiol. 21:2000;336-337.
17. National Committee for Clinical Laboratory Standards (1997). Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
18. Pfaller M.A., Diekema D.J., Messer S.A., Boyken L., Hollis R.J., Jones R.N. In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood. J Clin Microbiol. 41:2003;78-83.
19. Pfaller M.A., Messer S.A., Hollis R.J., Jones R.N., Doern G.V., Brandt M.E., Hajjeh R.A. Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States. Diagn Microbiol Infect Dis. 33:1999;217-222.
20. Sandven P., Bevanger L., Digranes A., Gaustad P., Haukland H.H., Steinbakk M. Constant low rate of fungemia in norway, 1991 to 1996. The Norwegian Yeast Study Group. J Clin Microbiol. 36:1998;3455-3459.
21. Sanglard D., Odds F.C. Resistance of Candida species to antifungal agents molecular mechanisms and clinical consequences . Lancet Infect Dis. 2:2002;73-85.
22. St. Germain G., Laverdiere M., Pelletier R., Bourgault A.M., Libman M., Lemieux C., Noel G. Prevalence and antifungal susceptibility of 442 Candida isolates from blood and other normally sterile sites results of a 2-year (1996 to 1998) multicenter surveillance study in Quebec, Canada . J Clin Microbiol. 39:2001;949-953.
23. Tietz H.J., Czaika V., Sterry W. Case report. Osteomyelitis caused by high resistant Candida guilliermondii. Mycoses. 42:1999;577-580.
24. Verduyn Lunel F.M., Meis J.F., Voss A. Nosocomial fungal infections candidemia . Diagn Microbiol Infect Dis. 34:1999;213-220.
25. Yang Y.L., Lo H.-J. Mechanisms of antifungal agent resistance. J Microbiol Immunol Infect. 34:2001;79-86.